310 related articles for article (PubMed ID: 21458311)
21. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Tscherry G; Jacky E; Jost LM; Stahel RA
Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
[TBL] [Abstract][Full Text] [Related]
22. [Single agent carboplatin therapy for advanced seminoma].
Kawakita M; Fukuzawa S; Terachi T; Hashimura T; Takeuchi H; Yoshida O
Hinyokika Kiyo; 1994 Jun; 40(6):493-7. PubMed ID: 8073956
[TBL] [Abstract][Full Text] [Related]
23. Re: An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.
Richie JP
J Urol; 2013 Oct; 190(4):1251. PubMed ID: 24029319
[No Abstract] [Full Text] [Related]
24. Primary chemotherapy for stage 2 testis cancer.
Abratt RP; McAdam GL; Pontin AR; Barnes RD; Ball HS
S Afr J Surg; 1997 Nov; 35(4):203-5; discussion 205-6. PubMed ID: 9540399
[TBL] [Abstract][Full Text] [Related]
25. [Results of chemotherapy and salvage surgery for advanced testicular cancer].
Saiki S; Meguro N; Maeda O; Kinouchi T; Kuroda M; Usami M; Kotake T; Miki T
Hinyokika Kiyo; 1999 Nov; 45(11):777-81. PubMed ID: 10637743
[TBL] [Abstract][Full Text] [Related]
26. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.
Tandstad T; Smaaland R; Solberg A; Bremnes RM; Langberg CW; Laurell A; Stierner UK; Ståhl O; Cavallin-Ståhl EK; Klepp OH; Dahl O; Cohn-Cedermark G
J Clin Oncol; 2011 Feb; 29(6):719-25. PubMed ID: 21205748
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of advanced testicular cancer and toxicity of chemotherapy].
Kawakita M; Matsuda T; Terachi T; Yoshida O
Hinyokika Kiyo; 1999 Nov; 45(11):783-6. PubMed ID: 10637744
[TBL] [Abstract][Full Text] [Related]
28. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
29. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
[TBL] [Abstract][Full Text] [Related]
30. Residual mass following chemotherapy of seminoma.
Horwich A; Paluchowska B; Norman A; Huddart R; Nicholls J; Fisher C; Husband J; Dearnaley DP
Ann Oncol; 1997 Jan; 8(1):37-40. PubMed ID: 9093705
[TBL] [Abstract][Full Text] [Related]
31. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
Brada M; Horwich A; Peckham MJ
Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
[TBL] [Abstract][Full Text] [Related]
32. [Management of advanced seminoma: retrospective study of 96 patients].
Bompas E; Fléchon A; Biron P; Droz JP
Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
[TBL] [Abstract][Full Text] [Related]
33. Two cycles of cisplatin-based chemotherapy for low-volume stage II seminoma: results of a retrospective, single-center case series.
Pichler R; Leonhartsberger N; Stöhr B; Horninger W; Steiner H
Chemotherapy; 2012; 58(5):405-10. PubMed ID: 23296381
[TBL] [Abstract][Full Text] [Related]
34. Two cycles of etoposide/cisplatin cured all patients with stage I testicular seminoma: risk-adapted protocol of the Hellenic Cooperative Oncology Group.
Bamias A; Aravantinos G; Deliveliotis C; Thanos A; Klouvas G; Antoniou N; Poulias I; Makatsoris T; Samantas E; Dimopoulos MA
Urology; 2007 Dec; 70(6):1179-83. PubMed ID: 18158042
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer.
Kleinschmidt K; Dieckmann KP; Georgiew A; Loy V; Weissbach L
Oncology; 2009; 77(1):33-9. PubMed ID: 19440001
[TBL] [Abstract][Full Text] [Related]
36. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions.
Giannis M; Aristotelis B; Vassiliki K; Ioannis A; Konstantinos S; Nikolaos A; Georgios P; Georgios P; Pantelis P; Meletios-Athanasios D
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1495-500. PubMed ID: 19437039
[TBL] [Abstract][Full Text] [Related]
38. Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).
Koutsoukos K; Tzannis K; Christodoulou C; Karavasilis V; Bakoyiannis C; Makatsoris T; Papandreou CN; Pectasides D; Dimopoulos MA; Bamias A
World J Urol; 2016 Jun; 34(6):853-7. PubMed ID: 26410826
[TBL] [Abstract][Full Text] [Related]
39. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Johnson D; Elson P; Einhorn LH; Trump D
J Clin Oncol; 1995 Feb; 13(2):470-6. PubMed ID: 7531223
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
